Demystifying HealthEquity: Insights From 11 Analyst Reviews
HealthEquity (NASDAQ:HQY) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 10 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 7 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $103.82, a high estimate of $110.00, and a low estimate of $92.00. This current average has increased by 5.83% from the previous average price target of $98.10.
Exploring Analyst Ratings: An In-Depth Overview
In examining recent analyst actions, we gain insights into how financial experts perceive HealthEquity. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Stan Berenshteyn | Wells Fargo | Raises | Overweight | $110.00 | $107.00 |
| C. Gregory Peters | Raymond James | Raises | Outperform | $105.00 | $100.00 |
| Scott Schoenhaus | Keybanc | Raises | Overweight | $100.00 | $95.00 |
| Stan Berenshteyn | Wells Fargo | Raises | Overweight | $107.00 | $105.00 |
| Alexander Paris | Barrington Research | Raises | Outperform | $105.00 | $100.00 |
| Sean Dodge | RBC Capital | Maintains | Outperform | $92.00 | $92.00 |
| Allen Lutz | B of A Securities | Raises | Buy | $105.00 | $97.00 |
| Constantine Davides | JMP Securities | Raises | Market Outperform | $105.00 | $101.00 |
| Mark Marcon | Baird | Raises | Outperform | $104.00 | $98.00 |
| Constantine Davides | JMP Securities | Announces | Market Outperform | $101.00 | - |
| Anne Samuel | JP Morgan | Raises | Overweight | $108.00 | $86.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to HealthEquity. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of HealthEquity compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of HealthEquity's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of HealthEquity's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on HealthEquity analyst ratings.
Discovering HealthEquity: A Closer Look
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
Breaking Down HealthEquity's Financial Performance
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: HealthEquity's revenue growth over a period of 3 months has been noteworthy. As of 30 April, 2024, the company achieved a revenue growth rate of approximately 17.66%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: HealthEquity's net margin excels beyond industry benchmarks, reaching 10.02%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.39%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): HealthEquity's ROA stands out, surpassing industry averages. With an impressive ROA of 0.9%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.47.
Analyst Ratings: Simplified
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.